
1. pharmacogenomics. 2016 nov;17(17):1903-1911. doi: 10.2217/pgs-2016-0131. epub
2016 oct 21.

the effect snps cyp450 chloroquine/primaquine plasmodium vivax malaria
treatment.

sortica va(1), lindenau jd(1), cunha mg(2), ohnishi md(3), ventura amr(3),
ribeiro-dos-santos âk(4), santos se(4), guimarães ls(5), hutz mh(1).

author information: 
(1)departamento de genética, universidade federal rio grande sul, porto
alegre, rs, brazil.
(2)laboratório de microbiologia e imunologia, universidade federal pará,
belém, pa, brazil.
(3)programa de ensaios clínicos em malária, instituto evandro chagas, sistema de 
vigilância sanitária, ministério da saúde, ananindeua, pa, brazil.
(4)laboratório de genética humana e médica, universidade federal pará, belém, 
pa, brazil.
(5)unidade de bioestatística, grupo de pesquisa e pós graduação, hospital de
clínicas de porto alegre, porto alegre, rs, brazil.

background: chloroquine/primaquine current therapy eliminate plasmodium
vivax infection amazon region.
aims: study investigates cyp1a2, cyp2c8, cyp2c9, cyp3a4 cyp3a5 genetic
polymorphisms influence cloroquine/primaquine treatment.
patients & methods: generalized estimating equations analyses performed to
determine genetic influence parasitemia and/or gametocytemia clearance
over treatment time 164 patients.
results: effect cyp2c8 low-activity alleles treatment observed (p = 
0.01). baseline first day treatment, wild-type individuals achieved
greater reduction gametocytes low-activity allele carriers. cyp2c9 and
cyp3a5 genes showed trend gametocytemia parasitemia clearance rates.
conclusion: future studies performed access extent cyp2c8,
cyp2c9 cyp3a5 gene polymorphisms influence cloroquine/primaquine
treatment.

doi: 10.2217/pgs-2016-0131 
pmcid: pmc7099632
pmid: 27767381 

